Literature DB >> 33371894

Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein.

Young-Joo Jin1,2, Habtamu Minassie Aycheh1, Seonggyun Han1, John Chamberlin1, Jaehang Shin1, Seyoun Byun1, Younghee Lee3,4.   

Abstract

BACKGROUND: Serum alpha-fetoprotein (AFP) is the approved serum marker for hepatocellular carcinoma (HCC) screening. However, not all HCC patients show high (≥ 20 ng/mL) serum AFP, and the molecular mechanisms of HCCs with normal (< 20 ng/mL) serum AFP remain to be elucidated. Therefore, we aimed to identify biological features of HCCs with normal serum AFP by investigating differential alternative splicing (AS) between HCCs with normal and high serum AFP.
METHODS: We performed a genome-wide survey of AS events in 249 HCCs with normal (n = 131) and high (n = 118) serum AFP levels using RNA-sequencing data obtained from The Cancer Genome Atlas.
RESULTS: In group comparisons of RNA-seq profiles from HCCs with normal and high serum AFP levels, 161 differential AS events (125 genes; ΔPSI > 0.05, FDR < 0.05) were identified to be alternatively spliced between the two groups. Those genes were enriched in cell migration or proliferation terms such as "the cell migration and growth-cone collapse" and "regulation of insulin-like growth factor (IGF) transport and uptake by IGF binding proteins". Most of all, two AS genes (FN1 and FAM20A) directly interact with AFP; these relate to the regulation of IGF transport and post-translational protein phosphorylation. Interestingly, 42 genes and 27 genes were associated with gender and vascular invasion (VI), respectively, but only eighteen genes were significant in survival analysis. We especially highlight that FN1 exhibited increased differential expression of AS events (ΔPSI > 0.05), in which exons 25 and 33 were more frequently skipped in HCCs with normal (low) serum AFP compared to those with high serum AFP. Moreover, these events were gender and VI dependent.
CONCLUSION: We found that AS may influence the regulation of transcriptional differences inherent in the occurrence of HCC maintaining normal rather than elevated serum AFP levels.

Entities:  

Keywords:  Alpha-fetoprotein; Alternative splicing; Hepatocellular carcinoma; RNA-sequencing

Mesh:

Substances:

Year:  2020        PMID: 33371894      PMCID: PMC7771076          DOI: 10.1186/s12920-020-00836-4

Source DB:  PubMed          Journal:  BMC Med Genomics        ISSN: 1755-8794            Impact factor:   3.063


  51 in total

Review 1.  Fibronectin: functional character and role in alcoholic liver disease.

Authors:  Razia S Aziz-Seible; Carol A Casey
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

3.  Alternative Splicing Signatures in RNA-seq Data: Percent Spliced in (PSI).

Authors:  Sebastian Schafer; Kui Miao; Craig C Benson; Matthias Heinig; Stuart A Cook; Norbert Hubner
Journal:  Curr Protoc Hum Genet       Date:  2015-10-06

4.  Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.

Authors:  Khairuddin Memon; Laura Kulik; Robert J Lewandowski; Edward Wang; Robert K Ryu; Ahsun Riaz; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Talia Baker; Michael Abecassis; Al B Benson; Mary F Mulcahy; Reed A Omary; Riad Salem
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

5.  Partial primary structure of bovine plasma fibronectin: three types of internal homology.

Authors:  T E Petersen; H C Thøgersen; K Skorstengaard; K Vibe-Pedersen; P Sahl; L Sottrup-Jensen; S Magnusson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

Review 6.  The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases.

Authors:  A Lelbach; Gy Muzes; J Feher
Journal:  Acta Physiol Hung       Date:  2005

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

9.  Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.

Authors:  Hye-Lin Kim; Jihyun An; Jae-A Park; Seung-Hoo Park; Young-Suk Lim; Eui-Kyung Lee
Journal:  Hepatology       Date:  2019-02-25       Impact factor: 17.425

10.  Serum fibronectin distinguishes the early stages of hepatocellular carcinoma.

Authors:  Hyunsoo Kim; JiYoung Park; Yongkang Kim; Areum Sohn; Injun Yeo; Su Jong Yu; Jung-Hwan Yoon; Taesung Park; Youngsoo Kim
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

View more
  2 in total

Review 1.  RNA splicing: a dual-edged sword for hepatocellular carcinoma.

Authors:  Anjali Kashyap; Greesham Tripathi; Avantika Tripathi; Rashmi Rao; Manju Kashyap; Anjali Bhat; Deepak Kumar; Anjali Rajhans; Pravindra Kumar; Darshan Shimoga Chandrashekar; Riaz Mahmood; Amjad Husain; Hatem Zayed; Alok Chandra Bharti; Manoj Kumar Kashyap
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

2.  Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma.

Authors:  Deepak Kumar; Manasi Das; Alexis Oberg; Debashis Sahoo; Panyisha Wu; Consuelo Sauceda; Lily Jih; Lesley G Ellies; Magda T Langiewicz; Supriya Sen; Nicholas J G Webster
Journal:  Adv Sci (Weinh)       Date:  2022-05-26       Impact factor: 17.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.